After a roller coaster ride, Sage COO strikes out on his own to chart a new biotech path
Three months after former Alnylam president Barry Greene took over Sage Therapeutics from Jeff Jonas, he’s losing his right-hand man.
Chief operating officer Mike Cloonan, who’s been with Sage for four years, has decided it’s time for him to pursue a CEO position in biopharma — though it’s unclear where yet. Greene and the rest of the team, he added, were supportive.
Since joining the Cambridge-based neuro biotech from Biogen, Cloonan had been put in charge of everything from commercial, portfolio and program management, medical affairs, technical operations, government affairs, corporate development and administrative functions — all aimed at shaping a solid business around the brain health drugs Sage had been developing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.